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CTCF is a ubiquitous 11-zinc-finger protein that plays a role in gene silencing or activation, chromatin insulation and genomic
imprinting. The CTCF gene has been mapped to the chromosome band 16q22.1 that shows frequent loss of heterozygosity in breast
cancer. The E-cadherin gene is the known tumour suppressor gene (TSG) at this region in lobular carcinomas; however, the target
gene in the more frequent ductal tumours is still unknown. Since CTCF targets include TSGs and oncogenes and it has the ability to
inhibit cell growth and proliferation, it has been suggested that it may be the target gene at the 16q22.1 in ductal carcinomas. In the
present study, tissue microarray technology was used to study the expression pattern of CTCF immunohistochemically in 344 cases
of invasive breast carcinoma and its expression was correlated with clinicopathological variables and patient outcome. Results showed
that breast tissues express CTCF in the parenchymal cells of the normal ducts and lobules but with a variable percentage of positive
cells. Staining of CTCF was detected in the nuclei and cytoplasm of the malignant cells, but no significant loss or decrease of
expression was noticed in association with any specific tumour type. There was a significant correlation between expression of CTCF
and histological grades; lower expression was associated with grade 3 tumours. Cytoplasmic expression was associated with
increased tumour size and with the presence of vascular invasion. However, no association was found between CTCF expression and
tumour type, lymph node stage, oestrogen receptor expression or patient outcome. In conclusion, the current results show that
CTCF, although it may play a role in breast carcinogenesis, is unlikely to be the TSG targeted by the 16q22.1 loss in breast cancer and
thus another gene or genes at this region remain to be identified.
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Loss of heterozygosity (LOH) at the long arm of chromosome 16
(16q) is one of the most frequent somatic genetic events in both
lobular and ductal carcinomas of the breast (Skirnisdottir et al,
1995; Cleton-Jansen et al, 2001). The smallest region of overlap at
16q in breast cancer has been located at 16q22.1 (Frengen et al,
2000), indicating the presence of a tumour suppressor gene (TSG)
at this region. In the search for the target gene, E-cadherin has
been proven to be the TSG by the identification of gene mutations
and loss of protein expression, but only in the lobular type
carcinomas (Kanai et al, 1994; Berx et al, 1995; Berx et al, 1998; Acs
et al, 2001). Thus, another TSG (s) is the target of 16q22.1 LOH in
the more frequent ductal carcinomas that remains to be identified.
Any gene located in the vicinity of 16q22.1 could be considered as
a candidate gene and should be examined to assess its role in
breast cancer.
The CTCF gene has been mapped to 16q22.1 (Filippova et al,
1998). It encodes a DNA-binding 11-zinc-finger protein that shows
a highly versatile function and multiple DNA sequence specificity
(Filippova et al, 1996, 1998). CTCF is a widely expressed
transcription factor that is involved in different aspects of gene
regulation including promoter activation (Vostrov and Quitschke,
1997) and repression (Filippova et al, 1996), hormone-responsive
gene silencing (Burcin et al, 1997), methylation-dependent
chromatin insulation and genomic imprinting (Kanduri et al,
2000; Filippova et al, 2002). In addition, it has been demonstrated
that CTCF can inhibit cell growth and induce cell cycle arrest at
multiple stages (Rasko et al, 2001).
The tumour suppressor role of CTCF was suspected because of
its involvement in regulating the expression of some genes that are
directly implicated in cancer (i.e., MYC, IGF2, p53, P27, p19/ARF
and BRCA1) (Bell and Felsenfeld, 2000; Klenova et al, 2002; Qi et al,
2003), its cell growth inhibitory effect and its genetic mapping to
16q22.1. In addition, some tumour-specific mutations have been
detected in some tumours including breast cancer (Ohlsson et al,
2001; Filippova et al, 2002). The role of CTCF in cancer has
previously been studied in some human tumours (Takai et al,
2001; Filippova et al, 2002; Yeh et al, 2002; Aulmann et al, 2003;
Ulaner et al, 2003); however, its role in breast cancer is still
unclear.
If CTCF was the target gene of 16q22.1 LOH in ductal carcinoma
of the breast, then we would predict that a large proportion of
ductal tumours might show marked or complete loss of its
expression compared with other histological types and/or with the
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snormal parenchymal tissues. Thus, in the present study, protein
expression of CTCF was examined immunohistochemically in a
large series to assess its possible role in invasive breast cancer.
MATERIALS AND METHODS
Patients and tumours
Formalin-fixed, paraffin-embedded tissue blocks were obtained
from 344 cases of invasive breast carcinoma available from the
Nottingham Tenovus Primary Breast Carcinoma Series. This is a
well-characterised series of primary operable invasive breast
cancer that has been previously used to study a wide range of
proteins including, recently, the CD59 protein (Madjd et al, 2003).
Patient’s clinical history and tumour characteristics including
tumour type (Ellis et al, 1992), size, histological grade (Elston and
Ellis, 1991), lymph node stage, Nottingham Prognostic Index (NPI)
and oestrogen receptor expression were obtained from the
database. Patients had a median age of 53 years (range 18–85
years). The tumours were as follows: 29 cases were pure lobular
(8.4%), 32 mixed lobular and ductal (9.3%), 214 ductal/no special
type (NST) (62.2%), five mixed NST and special type (1.5%), 12
tubular (3.5%), 42 tubular mixed (12.2%) and 10 cases mis-
cellaneous tumour types (2.9%). Survival data including survival
time, disease-free interval, development of distant metastasis and
recurrence was available for 294 patients. The median follow-up
time was 49.5 months (range 5–78 months). The NPI was
calculated using the following equation: NPI¼0.2 tumour size
(cm)þgrade (1–3)þlymph node score (1–3) (Galea et al, 1992).
This index predicts the survival of patients with invasive breast
cancer and may be divided into three groups: good prognosis
(p3.4), moderate prognosis (3.41–5.4) and poor prognosis group
(45.4) (Kollias et al, 1999).
Tissue arrays and immunohistochemistry
Tumour samples were arrayed as previously described (Kononen
et al, 1998). The tissue microarray blocks were constructed in three
copies, each containing one sample from a different region of the
tumour. In addition, whole tumour tissue blocks from 40 cases
were stained and used to examine CTCF expression in normal
breast tissues. Immunohistochemical staining was performed in
accordance with standard procedures on 4mm-thick sections.
Briefly, tissue slides were deparaffinised with xylene and then
rehydrated through three changes of alcohol. Endogenous
peroxidase activity was blocked by incubation in a 0.3% hydrogen
peroxide/methanol buffer. Antigen retrieval was carried out by
microwave treatment of the slides in sodium citrate buffer (pH 6.0)
for 20min. Then, the slides were rinsed in Tris-buffered saline
(TBS) (pH 7.6) and incubated with normal swine serum (NSS) in
TBS (1:5) to block nonspecific staining. The slides were then
incubated overnight with a goat polyclonal anti-CTCF antibody
(Santa Cruz Biotechnology, sc-5916) and used in an optimal
dilution of 1:100 (vv
 1 in NSS/TBS). After washing with TBS,
sections were incubated with the biotin-labelled secondary anti-
body (1:100) for 30min, and then avidin–biotin complex (1:100)
for a further 45min. 3-30Diaminobenzidine tetrahydrochloride was
used as a chromogen and the sections were counterstained with
Mayer’s haematoxylin.
To verify the specificity of the CTCF immunoreactivity, blocking
studies were performed by preincubation of the primary antibody
(at different dilutions) for 2h at room temperature with the
protein fragment used to raise it (Santa Cruz Biotechnology, sc-
5916 P) prior to its application to the tissues according to the
supplier data sheet protocol. This abolished staining of the
antibody (Figures 1 and 2). Preincubation with equivalent
concentration of an irrelevant peptide had no effect on immunos-
taining. To further confirm the subcellular localisation of the CTCF
protein, another primary antibody was used; a rabbit polyclonal
anti-CTCF antibody (AbCam Ltd, Cambridge, UK, ab 10571) in a
dilution of 1:20 for 2h incubation using the same staining
conditions as mentioned above. Negative control sections with
omission of the primary antibody were included and were
consistently negative. Tonsil and normal breast tissues were used
as positive controls.
Evaluation of immunohistochemical staining
CTCF staining was evaluated separately in the nuclei and cytoplasm
of the malignant cells. Assessment of the staining results was based
on a semiquantitative approach. A modified histochemical score
(H-score) was used for assessment (McCarty et al, 1985). This
includes a determination of both intensity of staining and
percentage of stained cells. For the intensity, a score index of 0,
1, 2 and 3 corresponding to absent, weak, moderate and strong
staining intensity was used and the percentage of positive cells at
each intensity was estimated. A final score of 0–300 was the
product of both the intensity and the percentage. Cutoff points of
expression was determined according to the histogram distribution
of the final scores. Two cores were evaluated from each tumour.
Each core was scored individually, and then the mean of the two
readings was calculated (Camp et al, 2000). The cases were scored
without knowledge of patient data by one observer on two separate
occasions and a good correlation between the results was found.
Figure 1 Expression of CTCF in the normal parenchymal cells of the
breast (dilution of the primary antibody was 1:50, overnight).
Figure 2 The same case after peptide blocking of the antibody showing
marked reduction of staining.
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Statistical analysis was performed using SPSS 10.0 statistical
software. Associations between clinicopathological variables and
expression of CTCF were analysed using the w
2 and Spearman rank
correlation tests. Correlation between protein expression levels
and overall survival and disease-free interval were analysed using
Kaplan–Meier curves with the differences estimated using the
Mantel–Cox log-rank test. A P-value of o0.05 was considered
significant.
RESULTS
CTCF expression in the breast
Results showed that breast tissues express CTCF in the parench-
ymal cells of the normal ducts and lobules but with a variable
percentage of positive cells. The staining pattern of the normal
tissue was mainly nuclear but cytoplasmic staining was also
evident in some cells. No membranous staining was detected.
Lymphocytes and endothelial cells showed positive staining
pattern. Malignant cells showed a heterogeneous nuclear and/or
cytoplasmic granular staining pattern (Figures 3–6). Normal
parenchymal cells in whole tissue sections as well as normal tissue
entrapped in the cores were used as internal controls. Only
staining of the invasive part of the tumours was considered. Both
anti-CTCF antibodies used in this study showed the same pattern
of staining and a significant correlation of their staining results
was noticed (Po0.001).
Cases were classified according to nuclear staining into two
groups; reduced (H-scoreo50), 202 cases (58.7%); and
positive (X50), 142 cases (41.3%); and according to cytoplasmic
staining into; reduced (H-scoreo100), 79 cases (23%); and
positive (X50), 265 cases (77%). There was a significant positive
correlation between nuclear and cytoplasmic staining of all
cases (r¼0.618, Po0.001). The nuclear and cytoplasmic
expression of CTCF in the malignant tissue varied between cases
with the positive cells varying in intensity and percentage, but no
specific pattern of staining or significant loss or decrease of
expression was noticed in association with any particular type of
breast cancer.
Figure 3 TMA showing expression of CTCF in the normal and
malignant tissues of the breast.
Figure 4 A case of ductal/NST carcinoma showing heterogeneous
pattern of positive nuclear staining of CTCF.
Figure 5 A case with positive cytoplasmic staining.
Figure 6 A case with reduced or weak staining of CTCF showing
positive staining of stromal cells.
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clinicopathological features in breast carcinoma
Table 1 shows the relationship between nuclear and cytoplasmic
expression of CTCF and the different clinicopathological features.
No correlation was found between CTCF expression and tumour
type divided into two groups; lobular (pure lobular and lobular
mixed) and nonlobular group (ductal, tubular, mixed and other
special types), or according to its specific histologic type
(w
2¼12.295, df¼8, P40.138 for nuclear expression and
Table 1 Correlation between CTCF expression and clinicopathological features
CTCF expression
Cytoplasmic v
2 Nuclear v
2
Variables No Negative Positive p-value Negative Positive p-value
1-Age (years)
o40 47 15 32 30 17
9.399 0.684
40–50 103 23 80 60 43
0.024 0.877
51–60 97 13 84 56 41
460 95 28 67 54 41
2-Tumour type
0.111 0.003
Lobular 61 15 46 36 25
0.739 0.959
Nonlobular 283 64 219 166 117
3-Size (cm)
4.662 2.592
p2 192 36 156 105 87
0.031 0.107
42 150 43 107 95 55
4-Grade
15 3 1 9 3 4 6.933 27 26 6.237
2 123 29 94 0.031 65 58 0.044
3 168 31 137 110 58
5-LN status
1.816 0.007
Negative 196 50 146 114 82
0.178 0.932
Positive 145 28 117 85 60
6-Stage
1 195 49 146 4.187 113 82 0.564
2 112 18 94 0.123 64 48 0.754
3 31 9 22 20 11
7-VI
7.344 1.063
No or probable 215 60 155 130 85
0.007 0.302
Definite 126 19 107 69 57
8-NPI
Poor 66 13 53 2.44 41 25 10.34
Moderate 180 37 143 0.295 116 64 0.006
Good 92 26 66 41 51
9-DM 0.009 0.748
No DM 262 51 211 0.923 152 110 0.387
Positive DM 32 6 26 16 16
10-LR
0.131 0.000
No LR 151 48 204 144 108
0.718 1.00
Positive LR 65 9 33 24 18
Lobular group¼pure lobular and lobular mixed; Nonlobular group¼ductal (NST), tubular, tubular mixed and other special types; LN¼lymph nodes; VI¼vascular invasion;
NPI¼ Nottingham Prognostic Index; DM¼distant metastasis; LR¼local and regional recurrence. Italic¼statistically significant.
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2¼5.109, df¼8, P40.746 for cytoplasmic expression). A
significant association was found between nuclear and cytoplasmic
expression and histological tumour grade. There was also a
correlation between cytoplasmic staining and age, tumour size and
the presence of vascular invasion and between nuclear staining and
NPI divided into three groups as described, with greater frequency
of positive cases in the good prognostic index group of patients
(P¼0.006). However, there was no association between CTCF
expression and lymph node stage, the development of distant
metastasis, oestrogen receptor expression (w
2¼1.56, P¼0.118 for
nuclear expression and w
2¼0.39, P¼0.694 for cytoplasmic
expression) or with patient outcome including local recurrence,
survival time or disease-free interval (Table 2). No association was
found between nuclear expression and age, tumour size or the
presence of vascular invasion or between cytoplasmic expression
and NPI.
DISCUSSION
Much effort has gone into evaluating the candidate TSG on 16q in
invasive ductal carcinoma of the breast, as well as in other tumours
that show frequent LOH of this chromosome arm. However, the
relevant genes have not been identified. CTCF is a potential target
gene because it has been mapped to the smallest region of overlap
at 16q in breast cancer (16q22.1) (Filippova et al, 1998). It encodes
protein involved in the transcriptional regulation of a wide variety
of target genes, several of which have been reported to be involved
in carcinogenesis (e.g. c-myc, p53, p27 and IGF2) (Ohlsson et al,
2001; Klenova et al, 2002). In addition, it has been shown to have a
profound growth retardation effect and can inhibit cell growth and
proliferation (Rasko et al, 2001). In the present study, protein
expression of CTCF has been studied immunohistochemically
(IHC) to evaluate its possible role in breast cancer as well as to
assess its prognostic value.
Our results showed that CTCF is expressed in both the nuclei
and cytoplasm of the malignant cells; nuclear expression was
detected in 41% of breast cancer cases and cytoplasmic expression
in 77%. Immunohistochemicl staining of CTCF in invasive ductal
carcinoma of the breast has previously been assessed by
Aulmann et al (2003), who reported moderate to strong nuclear
staining in 94.4% (17 out of 18). However, this high percent of
positive staining in their study may be related to the small number
of cases.
Previous studies of CTCF using immunofluorescence showed
nuclear localisation of its protein (Zhang et al, 2004), but no
cytoplasmic staining has been observed. Therefore, the cytoplas-
mic expression detected in our study might be either due
to unspecific staining or indicative of mutation affecting the
nuclear translocation of CTCF protein or as a result of post-
translational modification that is commonly found to attenuate
transcription factor (Hunter and Karin, 1992; Klenova et al,
2001). To rule out the first possibility, we tested the specificity
of the antibody binding using peptide blocking and we tried
another anti-CTCF antibody that recognises different epitope
and has been used before to study the phosphorylation pattern
in the C-terminus region of CTCF (Klenova et al, 2001). However,
our results confirmed the specificity of the observed staining
pattern.
Secondly, if this cytoplasmic expression of CTCF was an
indication of mutation or inactivity that has any significant
tumour suppressor role in a particular tumour type, we would
expect an association between the pattern of expression (nuclear,
cytoplasmic or reduced) and the tumour type. However, we could
not detect any association between the intensity or pattern of
expression of CTCF and tumour type and there was neither
marked nor complete loss of expression in any specific type,
suggesting that CTCF is not the likely TSG in breast cancer. These
results are consistent with those of Yeh et al (2002) and Cui et al
(2001) who could not detect mutations or loss of CTCF mRNA in
Wilms’ tumours and with those of Aulmann et al (2003) who used
immunohistochemistry, allelic studies and mutation screen of the
CTCF gene and did not find loss of CTCF protein expression in
invasive ductal carcinoma of the breast.
In the current study, we detected an association between
expression of CTCF and histological grade where a high percentage
of low-grade tumours that have a less proliferative activity showed
positive nuclear expression, while the high-grade tumours mainly
showed reduced or absent expression. We also found a correlation
between positive cytoplasmic expression and tumours of smaller
size. These results are consistent with the previous reports that
showed the ability of CTCF to inhibit cell growth and proliferation
(Rasko et al, 2001). Although we found a correlation between
nuclear expression of CTCF and NPI group and between
cytoplasmic expression and vascular invasion, we did not find
any significant correlation between its expression and other
prognostic markers of breast cancer such as lymph node stage
or with patient outcome.
In conclusion, our data indicate that CTCF may have a role in
breast cancer progression but it is not likely to be the gene that is
targeted by 16q22.1 LOH in breast cancer. Further studies of other
genes at this region are required to identify the TSG that is the
target of 16q22.1 loss in ductal carcinoma of the breast.
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